ASCIMINIB (SCEMBLIX) Nursing Considerations

Join NURSING.com to watch the full lesson now.

Included In This Lesson

Outline

What is the Generic Name

ASCIMINIB

What is the Trade Name for ASCIMINIB

SCEMBLIX

What is the Indication for ASCIMINIB

  • 1 INDICATIONS AND USAGE SCEMBLIX is indicated for the treatment of adult patients with: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). This indication is approved under accelerated approval based on major molecular response (MMR) [see Clinical Studies (14.1)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Ph+ CML in CP with the T315I mutation. SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). ( 1 ) This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Ph+ CML in CP with the T315I mutation. ( 1 )

 

 

View Our Nursing Pharmacology Course

 

References: https://open.fda.gov/

 

Other Pharm Resources
Join NURSING.com to watch the full lesson now.
[NextGen]
[NextGen]